CClinicalTrials.gg
CompletedNCT07335978PCDSUpdated May 4, 2026

Chair Exercise and Intergenerational Activities in Older Adults With Physio-Cognitive Decline Syndrome

An interventional study of Intervention 1 in Cognitive Frailty, sponsored by Atma Jaya Catholic University of Indonesia. Completed at 1 site in Indonesia. Open to participants aged 60 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Atma Jaya Catholic University of Indonesia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2025, registered Jan 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
60 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to investigate the effects of chair exercise followed by intergenerational activity in frailty syndrome and changes in serum mBDN levels among older adults with Physio-Cognitive Decline Syndrome (PCDS), as a novel approach integrating physical and social intervention with biomolecular assessments

In older adults with PCDS

  1. Does A 16-week program of chair exercise followed by intergenerational activity improve handgrip strength (HGS), gait speed, MoCA-Ina scores, and health-related quality of life?
  2. Does a 16-week program of chair exercise followed by an intergenerational activity increase serum mBDNF level?
  3. Are serum mBDNF levels associated with MoCA-Ina scores, gait speed, and handgrip strength?

Intervention Group

Participants will undergo a 12-week structured chair exercise program, conducted with a trained exercise instructor and supervised by a physician for vital sign monitoring during each session. The frequency of sessions will increase progressively:

  • Weeks 1-2: once weekly
  • Weeks 3-6: twice weekly
  • Week 7-12: three times weekly

Additional activities include (intervention and control group):

  • Weeks 1 and 11: teleconference session on nutrition and physical exercise supported by electronic flyers (e-flyers).
  • Weeks 3, 5, 7, 11, and 13: distribution of e-flyers on elderly nutrition and the muscle-brain axis.

Additional Activity (intervention group)

- Weeks 13-16: intergenerational activities at an orphanage with children aged >5 years

Assessments (intervention and control group):

  • Week 1: serum mBDNF and HbA1c measurement
  • Week 12 and 16: physical assessments (body weight, height, handgrip strength, gait speed, MoCA-Ina, and IADL) and serum mBDNF measurement.

Control Group:

The participant will receive general health education on performing physical exercise 1-3 times per week throughout week 1-16

Read the detailed description

Population aging in Indonesia has led to a growing proportion of older adults experiencing functional and cognitive decline. Physio-cognitive decline syndrome (PCDS), defined as the coexistence of reduced physical performance (such as slow gait speed or weak handgrip strength) and mild cognitive impairment without disability or dementia, is considered an early and reversible stage that increases the risk of frailty, disability, and poor quality of life.

Chair exercise provides a safe and feasible intervention for older adults, with proven benefits in muscle strength, balance, and neurocognitive function, partly mediated through increased levels of brain-derived neurotrophic factor (BDNF). In parallel, an intergenerational activity involving direct interaction between older and younger individuals has shown promise in improving psychosocial well-being and cognitive outcomes.

This study integrates chair exercise with intergenerational activities to target the multidimensional nature of PCDS. Outcomes will focus on frailty status and changes in serum mature brain-derived neurotrophic factor (mBDNF) to establish a multimodal, culturally adapted strategy to support healthy aging in Indonesian older adults.

02

Conditions studied

  • Cognitive Frailty
03

In context

Lead sponsor

This is the only study on the registry with Atma Jaya Catholic University of Indonesia as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • Aged 60-75 years
  • Meet diagnostic criteria for physio-cognitive decline syndrome (PCDS): gait speed \<1.0 m/s and/or hand grip strength \<28 kg (men) or \<18 kg (women), and MoCA-Ina score 22-26
  • Instrumental Activities of Daily Living (IADL) score >5
  • Able to understand and follow instructions adequately
  • Willing to participate and provide written informed consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Intervention Arm

    Nutritional education + 12 weeks structured chair-based exercise (PEROSI protocol, progressive frequency from 1 to 3 sessions/week, 60 minutes/session, supervised online) followed sequentially by 4 weeks SHP-based intergenerational activities (8 sessions, 2x/week, 45 minutes/session, paired 1:1 elderly-child using AMIR educational materials at selected orphanages).

    Behavioral: Intervention 1

  • No intervention
    Control Arm

    Nutritional education only (2 personalized dietitian tele-conferences at weeks 1 and 11; 5 educational e-flyers at weeks 3, 5, 7, 13, and 15)

Interventions

  • BehavioralIntervention 1

    Nutritional education + 12 weeks structured chair-based exercise (PEROSI protocol, progressive frequency from 1 to 3 sessions/week, 60 minutes/session, supervised online) followed sequentially by 4 weeks SHP-based intergenerational activities (8 sessions, 2x/week, 45 minutes/session, paired 1:1 elderly-child using AMIR educational materials at selected orphanages).

06

What researchers measure

Primary outcomes

  1. Frailty Syndrome Status

    • Change in frailty syndrome status (assessed using Cardiovascular Health Study criteria: score 0 robust, 1-2 pre-frail, ≥3 frail) from baseline to week 16.

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. serum mature brain-derived neurotrophic factor (mBDNF)

    Change in serum mature brain-derived neurotrophic factor (mBDNF) levels (measured by ELISA) from baseline to week 16.

    Time frame: from baseline to week 16

Secondary outcomes

  1. Hand grip strength

    Change in hand grip strength (in kilogram; dominant hand, best of 3 trials using hand dynamometer) from baseline to week 16.

    Time frame: from baseline to week 16

  2. Gait Speed Test

    Change in gait speed (m/s; average of 2 trials over 6-meter walk test) from baseline to week 16.

    Time frame: baseline to week 16

  3. Cognitive Function

    Change in cognitive function (MoCA-Ina total score, range 0-30)

    Time frame: from baseline to week 16

  4. health-related quality of life (SF-12 questionnaire)

    Change in health-related quality of life (SF-12 questionnaire)

    Time frame: from baseline to week 16

  5. serum mBDNF levels

    Correlations between changes in serum mBDNF levels and changes in MoCA-Ina score, hand grip strength, and gait speed.

    Time frame: baseline to week 16

Other outcomes

  1. Adherence to exercise sessions

    Adherence to exercise sessions

    Time frame: from baseline to week 12

  2. Intergenerational activities

    Adherence to intergenerational activities (attendance logs)

    Time frame: from weeks 13 to weeks 16

  3. Physical Activity Scale for the Elderly, PASE

    Physical activity level (Physical Activity Scale for the Elderly, PASE) is an easily administered and scored instrument that measures the level of physical activity in individuals aged 65 years and older. PASE Scored may range from zero to 400 or more

    Time frame: from baseline to week 16

  4. Depressive Symptoms

    The Geriatric Depression Scale-15 (GDS-15) is a widely used, self-report screening tool designed identify depression in older adults. The 15-item version (GDS-15) is common, and Patients answer "yes" or "no" to 15 questions regarding how they felt over the past week. Interpretation: 1. 0 - 4: Normal 2. 5 - 10: Mild to moderate depression 3. 11 - 15: Severe Depression

    Time frame: from baseline to week 16

  5. Loneliness

    The questionnaire of De Jong Gierveld Loneliness Scale, Indonesian version is a concise tool designed to capture both emotional and social dimensions of loneliness. The total loneliness score can be categorized into four levels: not lonely (Score 0, 1 or 2), moderate lonely (score 3 through 8), severe lonely (score 9 or 10), and very severe lonely (score 11)

    Time frame: From baseline to weeks 16

  6. Quality of Life Additional Domains

    Questionnaire of Quality of life additional domains (EQ-5D-5L) is a brief, multiattribute, generic, health status measure composed 5 questions with likert response options (descriptive system). EQ-5D-5L index scores range from -0.59 to 1, where 1 is the best possible health state

    Time frame: from baseline to week 16

  7. Charison Comorbidity Index (CCI)

    The questionnaire of the Charlson Comorbidity Index (CCI) predicts the mortality for a patient who may have a range of concurrent conditions (comorbidities), such as heart disease, AIDS, or cancer (considering a total of 17 categories). Based on the CCI scores, the severity of comorbidity was categorized into three grades: mild, with CCI scores of 1-2, moderate, with CCI scores of 3-4, and severe, with CCI scores ≥5

    Time frame: baseline

07

Study locations

1 site
  • Catholic Church of St. Anthony of Padua, Bidaracina, GKI Depok, Catholic Church of St. Anna, Catholic Chrusch St. Aloysius Gonzaga
    Jakarta, Jakarta Special Capital Region, Indonesia
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Dec 28, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07335978
Lead sponsor
Atma Jaya Catholic University of Indonesia
Responsible party
Agnes Rensa (Princial Investigator, Atma Jaya Catholic University of Indonesia) — Principal investigator
First posted
Jan 13, 2026
Start date
Sep 24, 2025
Primary completion
Mar 16, 2026
Completion
Mar 16, 2026
Last update
May 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion